Zhangyining2 (Talk | contribs) |
|||
Line 224: | Line 224: | ||
<div class="second_s container-fluid"> </div> | <div class="second_s container-fluid"> </div> | ||
<!--屏幕内容第三条 overview 从此不全屏--> | <!--屏幕内容第三条 overview 从此不全屏--> | ||
+ | <div style="padding:5rem 0;font-size:3rem;">HumanPractices</div> | ||
<div style="padding: 7.5vw"><img src="https://static.igem.org/mediawiki/2019/b/bc/T--Jilin_China--HP--HP_Overview.svg" width="100%" style=" margin: 0 auto"></div> | <div style="padding: 7.5vw"><img src="https://static.igem.org/mediawiki/2019/b/bc/T--Jilin_China--HP--HP_Overview.svg" width="100%" style=" margin: 0 auto"></div> | ||
<!--屏幕内容第三条 overview 从此不全屏--> | <!--屏幕内容第三条 overview 从此不全屏--> |
Revision as of 03:46, 22 October 2019
Team
Project
Lab
Model
Parts
HP
Judging
HumanPractices
Preliminary Brainstorming
At the beginning of brainstorming, there were several research topics available, such as the treatment of vaginitis, the improvement of plant resistance and killing Beauveria bassiana. We expected to choose the most meaningful project that could be turned into a product.
Killing Beauveria Bassiana
Plant Resistance Improvement
Vaginitis Treatment
A lecture on Women's Health on March 8
![](https://static.igem.org/mediawiki/2019/6/67/T--Jilin_China--HP--1.jpeg)
Questionnaire
![](https://static.igem.org/mediawiki/2019/9/93/T--Jilin_China--HP--map.png)
Data show that more than 74% of those who have suffered from gynecological diseases have suffered from vaginitis. Of all vaginitis, vulvovaginal candidiasis (VVC) is the most prevalent.
Research Plan of VVC
After defining the research direction of vulvovaginal candidiasis, we decided to choose vulvovaginal candidiasis as our research subject. We intended to base our project on the current treatment methods and problems of vulvovaginal candidiasis. Therefore, we interviewed doctors and surveyed patients to get a full picture of this disease.
Current treatment situation
For the professional advice and actual situcation about this disease, we make the medical specialist and patient interviews to get the information we need.
Doctor interview
Zongxiang Leng, PhD, MD
Deputy Dean of Jilin Maternal and Child Health Hospital, Gynaecologist.
Process
![](https://static.igem.org/mediawiki/2019/e/e9/T--Jilin_China--HP--lzxp.jpeg)
Patient interview
![](https://static.igem.org/mediawiki/2019/8/82/T--Jilin_China--HP--brp.jpeg)
Initial Design
With the shortcomings of the current treatment methods for VVC in mind, we conducted a mid-term brainstorming aiming at the problems of recurrence and adverse reactions, then we put forward initial design:
Sensing system
Therapeutic system
① -BDSF
② -Msp1
③ -β-1,3-Glucanase
④ - Nad1
Suicide switch
Therapeutic system
① -BDSF
② -Msp1
③ -β-1,3-Glucanase
④ - Nad1
Suicide switch
The polish of design
Exprimental promotion
Expert Consultant
Hongyu Xiang, PhD
Professor, School of Life Sciences, Jilin University, Microbiology, Microbial and Biochemical Pharmacy specialist.
Process
![](https://static.igem.org/mediawiki/2019/2/24/T--Jilin_China--HP--xhyp.jpeg)
Improvement
1. We chose the antibacterial peptide LL-37, which has already expressed in the engineered bacteria to replace Nad1.
2. We selected the secretory expression vector pVE5523 as the destination vector.
2. We selected the secretory expression vector pVE5523 as the destination vector.
Yinqiu Cui, PhD
Professor, Vice-Dean of College of Life Sciences, Jilin University, Molecular biology expert.
Process
In order to sense the presence of C. albicans, we designed the sensing system, which can detect the 4-HPA secreted by C. albicans, and then activate the PBC promoter to initiate transcription of various parts of the therapeutic system. However, while searching for the sequence of the PBC promoter, we found that there were much unintentional sequences between the start of the PBC promoter and the end of the previous gene. So we considered truncating the middle part of the sequence and asked Dr. Cui about this idea. Dr. Cui expressed appreciation for our design ideas but reminded us: "It is very likely that changing the sequence in front of the promoter may affect the normal start of the promoter." Therefore, she recommended that we keep all the sequences and do not delete them arbitrarily.
Improvement
1. We abandoned the idea of truncating the sequence in the front of the promoter.
2. We decided to change the promoter in the treatment system to a constitutive promoter so that we could easily conduct experiment to verify individual parts.
2. We decided to change the promoter in the treatment system to a constitutive promoter so that we could easily conduct experiment to verify individual parts.
Comprehensive evaluation
Design determination
After interviewing two professors, our design has been greatly improved according to the proposal from Dr. Cui and Dr. Xiang. The design is as follows:
Sensing system
Therapeutic system
① -BDSF
② -Msp1
③ -β-1,3-Glucanase
④ - LL-37
Suicide switch
Therapeutic system
① -BDSF
② -Msp1
③ -β-1,3-Glucanase
④ - LL-37
Suicide switch
Therefore, we hope our project can be comprehensively evaluated from ethics, experimental safety and other aspects.
Overall evaluation
Feng Gao, PhD, MD
Professor, Director of National Engineering Laboratory for AIDS Vaccine, College of Life Sciences, Jilin University, Immunologist.
Process
![](https://static.igem.org/mediawiki/2019/8/85/T--Jilin_China--HP--gfp.jpeg)
Improvement
1. We prepared to make the medicine into a vaginal capsule or vaginal gel by using a probioties preparation process. Engineered bacteria will exert their function in the vaginal environment and kill C. albicans for therapeutic purposes.
2. We have planned a series of interviews with pharmaceutical companies.
Xianghui Yu, PhD
Professor and Dean of School of Life Sciences, Jilin University,
Biochemist.
Process
![](https://static.igem.org/mediawiki/2019/e/ef/T--Jilin_China--HP--yxhp.jpeg)
Improvement
1. We prepared to make the medicine into a vaginal capsule or vaginal gel by using a Probioties preparation process. Engineered bacteria will exert their function in the vaginal environment and kill C. albicans for therapeutic purposes.
2. We have planned a series of interviews with pharmaceutical companies
2. We have planned a series of interviews with pharmaceutical companies
Safety Operation Regulation
Since our experiment involves fungi, we need stricter laboratory safety regulations. With the assistance of laboratory safety experts, the laboratory safety specifications have been formulated and all the experimenters have been informed. Otherwise, the experiment will not be carried out. Dr. Jiang and Dr.Chen helped us with our regulations. Under the guidance of Dr. Jiang and Dr.Chen, we consulted the relevant laws of China. Organisms used in our project are commonly and widely used strains, so their safety are thus guaranteed. Click here for more information.
Ethics Consideration
Yanyan Li, PhD
Chief pharmacist, first Hospital of Jilin University, Ethics expert.
Process
![](https://static.igem.org/mediawiki/2019/8/86/T--Jilin_China--HP--lyyp.jpeg)
Application perspective
We hope that our project will be applied in the future, so we have established interviews with pharmacies,Pharmaceutical Enterprises,and doctor to make our project more practical.
Pharmacy interview
Process
![](img/ydp.jpg)
Therepeutic evaluation
Tianmin Xu, PhD, MD
Deputy Director of Gynecology and Obstetrics, Second Hospital of Jilin University, Gynecologist.
Process
![](https://static.igem.org/mediawiki/2019/f/f3/T--Jilin_China--HP--xtmp.jpeg)
Pharmaceutical Enterprises interview
Process
![](https://static.igem.org/mediawiki/2019/d/d3/T--Jilin_China--HP--gzjp.jpeg)
Improvement
1. We added the experimental verification part of bacteriostasis circle.
2. We have adjusted our experimental proof scheme according to the relevant national batches.
2. We have adjusted our experimental proof scheme according to the relevant national batches.